Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension

NCT ID: NCT01527760

Last Updated: 2012-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To estimate the effectiveness of Viscum album Homoeopathic mother tincture in Essential Hypertension by conducting clinical trial in moderate hypertensive patients for a period of six weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)

Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertension at the range 180-120 mm of Hg for Systole \&
* 110-80 mm of Hg for Diastole

Exclusion Criteria

* Patients who are on ACEI / ARB for Hypertension
* Diseases in which life expectancy is less than six months
* Secondary hypertension
* CHD
* Family History of Mental Illness like Anxiety or depression.
* Nasal Congestion
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rajiv Gandhi University of Health Sciences

OTHER

Sponsor Role collaborator

Fr Muller Homoeopathic Medical College

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Kurian P J

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Kurian P John, MD

Role: PRINCIPAL_INVESTIGATOR

Fr Muller Homoeopathic Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fr Muller Homoeopathic Medical College Hospital

Mangalore, Karnataka, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

References

Explore related publications, articles, or registry entries linked to this study.

Poruthukaren KJ, Palatty PL, Baliga MS, Suresh S. Clinical evaluation of Viscum album mother tincture as an antihypertensive: a pilot study. J Evid Based Complementary Altern Med. 2014 Jan;19(1):31-5. doi: 10.1177/2156587213507726. Epub 2013 Nov 5.

Reference Type DERIVED
PMID: 24647376 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RGUHS2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Spermidine Anti-Hypertension Study
NCT04405388 UNKNOWN PHASE3